NK Cell Senotherapy
NK Cell Consultation · Filed Plan PB3250244

Review immune context
before any NK option.

NK cells (Natural Killer cells) are part of the immune system's surveillance function. At Cellforce One, NK-related consultation begins with medical history, cancer history, current treatment status, screening results, and physician explanation. If appropriate, the route is intravenous infusion under the filed Category III plan PB3250244.

Filed / notified under Japan's Act on Safety of Regenerative Medicine — Category III plan PB3250244. Out-of-pocket / private treatment. Diagnosis, prescription, and treatment decisions are made through physician consultation.

Book a consultation arrow_forward View treatment flow Read the science
Why NK

Why NK cells are reviewed.

01

Frontline immune surveillance

NK cells are discussed in immune-surveillance research. This is used as background for physician explanation, not as a standalone treatment decision.

02

SASP and chronic inflammation

Research discusses senescent-cell biology, SASP, inflammation, and aging-related changes. Individual relevance must be reviewed medically.

03

Filed IV route, if appropriate

If considered after screening, NK cell therapy is explained as an intravenous route within the filed provision framework. Individual results vary.

Mechanism

Research background
for physician explanation.

The following mechanisms are discussed in immune-surveillance research. They are not presented as proof of an individual effect.

Receptor 01

NKG2D

Research discusses NKG2D ligands such as MICA/B and ULBP as immune-surveillance signals.

Receptor 02

DNAM-1

Activating receptor recognizing PVR / Nectin-2. Research suggests a complementary role to NKG2D in senescent cell recognition.

Receptor 03

NKp46

A natural cytotoxicity receptor (NCR). Research suggests NKp46 recognizes specific ligands on senescent cell surfaces and contributes to immune surveillance.

Effector

Perforin and
Granzyme B

Perforin forms pores in target cell membranes; granzyme B enters and induces apoptosis. Research suggests selective targeting with limited impact on healthy cells.

The mechanisms above describe pathways suggested by basic research. Clinical effects vary by individual; a specific outcome is not promised.

CFO Quality · CANK Protocol

Autologous NK culture at CFO.

CFO delivers autologous NK cell therapy by combining the CANK protocol, partner cell-processing infrastructure, and physician-led indication review.

01 · Autologous Pathway

Your own cells, only

All NK cells used are derived from the patient. Allogeneic (donor) NK cells are not used. Research suggests autologous-derived therapy carries lower immune rejection risk.

02 · CANK Protocol

CANK activation protocol

Activation culture using IL-2 and autologous plasma — designed to enhance expression of NKG2D, DNAM-1, and NKp46 receptors. Performed under partner CPC quality controls.

03 · Scientific Supervision

Academic supervision

CANK protocol supervised by Dr. Tsutomu Nakazawa (Grandsoul Research Institute; author, Frontiers in Immunology 2025). Culture design reflects basic research and clinical experience.

04 · Filed Pathway

Filed (PB3250244)

Filed / notified under Japan's Act on Safety of Regenerative Medicine — Category III, plan number PB3250244. Filing represents the provider framework, not national endorsement of treatment effect.

DDR Protocol

Detect → Review → Rebuild.

NK cell senotherapy is the "Review" step in the DDR protocol. Before infusion, screening (Detect) is essential to confirm indication.

Step 01

Detect

Precision diagnostics (MRI, blood, biomarkers) establish your baseline. Indication and priority for NK infusion are determined in physician consultation.

Step 02 · This page

Review

Activated autologous NK cells (CANK protocol) are administered intravenously. Research suggests reinforced immune surveillance against senescent and abnormal cells.

Step 03

Rebuild

Where appropriate, MSC (mesenchymal stem cells) and autologous EVs (extracellular vesicles) support tissue repair. Sequencing is designed individually in physician consultation.

Pre-treatment screening (examples)
  • ●Blood panel (CBC, biochemistry, coagulation)
  • ●Infectious disease screening (HBV / HCV / HIV / HTLV-1, etc.)
  • ●Inflammation markers (hs-CRP, etc.)
  • ●Imaging (MRI / CT) where indicated
Evidence · 6 peer-reviewed papers

NK-focused evidence (6 papers).

Six peer-reviewed papers covering NK-related immune surveillance and senescent-cell research. Citations are research background and do not promise individual outcomes.

Frontiers in Immunology · 2025 · Nakazawa T, et al.

Natural Killer Cell-based Senotherapy: A Promising Strategy for Healthy Aging

Research discusses how activated NK cells recognize senescent-cell-related signals via NKG2D and DNAM-1 receptor pathways.

Read on Frontiers →
Nature Aging · 2024

Senescent Cells Evade NK Surveillance via GD3

Research suggests molecular mechanisms by which senescent cells evade NK-mediated immune surveillance with age, framing the rationale for reinforcing NK function.

Read on Nature Aging →
Nature · 2021

Aging Immune Cells Drive Systemic Aging

Research suggests immune system aging is associated with accelerated aging across organ systems, framing immune function as a systemic health indicator.

Read on Nature →
Nature · 2023

NK Cells Recognize Senescent Cells via Immune Surveillance

Research describes how NK cells recognize specific ligands on senescent cell surfaces as part of immune surveillance pathways.

Read on Nature →
Frontiers in Immunology · 2022

Autologous NK Cell Infusion and NKG2D / DNAM-1 Receptor Profile

Research suggests an association between NKG2D and DNAM-1 receptor expression on activated NK cells and senescent cell recognition performance.

Read on Frontiers →
Cell Death & Disease · 2022

Autologous NK Cell Therapy Reduces Senescence Markers via Apoptosis Pathways

Research describes apoptosis induced by perforin and granzyme B released by NK cells as a mechanism of senescent cell elimination.

Read on Cell Death & Disease →
View full evidence (8 papers) arrow_forward
Treatment Flow

From review to follow-up.

01

Consultation

Goals, history, cancer history, current care, and prior assessment results are shared in physician consultation. Suitability and alternatives are reviewed individually.

02

Blood draw

Approximately 30 mL of peripheral blood is collected and transported to the CPC the same day for PBMC isolation.

03

CANK culture

Cell-processing details, timing, quality documents, and route are explained individually when NK therapy is selected after physician review.

04

Infusion

Activated NK cells are administered as an intravenous infusion (typically 60–90 minutes), followed by brief observation.

05

Follow-up

Biomarkers and self-reported indicators are reassessed 1–3 months post-infusion. Continued tracking is supported via Monthly Longevity Review.

After Treatment

Track your
post-treatment journey.

Follow-up may include inflammation markers, biomarkers, self-reported indicators, and medical-record organization when the physician considers them useful.

The CFO Monthly Longevity Review is a member program that organizes your health data monthly during your stay in Japan and after you return home, with periodic review by Japanese physicians. We offer enrollment as a post-treatment follow-up option.

CFO Monthly Longevity Review
  • ●Monthly organization of food, sleep, symptoms, photos, and lab values
  • ●Review of post-NK inflammation markers and self-reported logs
  • ●Monthly physician review by Japan-based doctors
  • ●Optimization of timing for your next visit to Japan
View Monthly Review arrow_forward
FAQ

Frequently asked questions.

Q1. What is NK cell senotherapy?

A filed Category III regenerative-medicine option in which NK cells may be prepared from the patient's blood and administered by intravenous infusion when appropriate after physician review.

Q2. What does "senotherapy" mean?

A portmanteau of "senescent" + "therapy" — therapeutic strategies targeting senescent cells. NK-based senotherapy uses immune cells rather than small molecules.

Q3. What is the CANK protocol?

When NK therapy is considered, the physician explains the preparation method, cell-processing route, risks, costs, and alternatives. Public information does not replace individual medical judgment.

Q4. How soon do effects appear?

Individual results vary. Research findings are background information and do not promise a specific outcome.

Q5. How many sessions are required?

Determined per individual through physician consultation. Options range from a single infusion to multi-session protocols based on goals, condition, and assessment results.

Q6. What reactions or risks should I discuss?

Transient reactions such as fever or fatigue may occur with infusion-based procedures, and other risks can differ by condition. The physician explains possible risks and alternatives before any treatment decision.

Q7. Is this a substitute for cancer treatment?

No. NK therapy is not a substitute for standard cancer care. Research suggests potential support for the immune environment, but it is offered as concurrent or complementary support to standard care, with diagnosis and treatment decisions made by physicians on an individual basis.

Q8. Can I receive treatment from overseas?

Yes. Pre-arrival consultation via WhatsApp or email, followed by blood draw → culture → infusion scheduled around your Japan visit. You may return home during the culture period and come back for infusion.

Q9. Is post-treatment follow-up available?

Biomarker follow-up (NK activity, CRP, etc.) is recommended. For ongoing monitoring, we offer enrollment in the CFO Monthly Longevity Review.

Q10. What does filed / notified mean?

The NK provision plan is filed / notified as a Category III regenerative medicine provision plan (PB3250244) under Japan's Act on Safety of Regenerative Medicine. Filing represents the provider framework, not national treatment-effect endorsement.

Important Notes

Before you proceed.

Get Started

Start with a consultation.

A physician consultation reviews your current health status, records, screening needs, risks, costs, and whether NK-related consultation is appropriate.

Email us arrow_forward Chat on LINE Chat on WhatsApp Monthly Review

Domestic patients prefer LINE; international patients typically use WhatsApp.

Official References

Public registry and official channels.

These links point to Japan's public registry pages for filed regenerative-medicine provision plans and to the clinic's official YouTube / Instagram channels. Registry publication is a reference for filed provision-plan information; it is not evidence of individual treatment outcomes or absence of risk.

Category II list Category III list YouTube Instagram